Previous 10 | Next 10 |
Independent Report Acknowledges That Sarissa’s Campaign to Remove Amarin’s Chairman and De Facto Seize Board Control Would be Detrimental to Shareholder Value Board Urges Shareholders to Follow ISS and Glass Lewis's Recommendations and Vote “AGAINST” Al...
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today corrected the record regarding the latest misinformation from Sarissa Capital Management (“Sarissa”). Contrary...
Sarissa Assumes That Amarin Knew This Conduct Was Going On and Did Nothing To Stop It Sarissa Acted to Correct the Issue, Ensuring That All Votes Submitted On The Blue Proxy Card Will Be Counted at the Amarin General Meeting Amarin Shareholders That Already Voted on the Blue Proxy...
Amarin Corporation plc (AMRN) SVB Securities Global Biopharma Conference February 14, 2023 10:40 AM ET Company Participants Karim Mikhail - President & CEO Tom Reilly - Chief Financial Officer Conference Call Participants Roanna Ruiz - SVB Securities ...
Sarissa Believes Amarin Board Missed an Opportunity for its First True Engagement with Frustrated Shareholder Base Sarissa Points to Several Statements Made by the Amarin Board Which Demonstrate a Complete Lack of Understanding of the Reality for Amarin Shareholders Sarissa ...
The following slide deck was published by Amarin Corporation plc in conjunction with this event. For further details see: SVB Securities Global Biopharma Conference
Glass Lewis Recognizes that Change Led by Amarin’s New Board is Already Underway, and Sarissa Representation is Not Warranted Report Notes that Sarissa’s Underqualified Slate of Nominees Include “Redundant” Skillsets Amarin Board Urges Shareholders to...
-- Board and Management Team to Answer Shareholder Questions -- DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that members of its Board of Directors and...
If You Already Voted a Proxy Card “FOR” the Sarissa Nominees and “FOR” the Removal of Chairman Per Wold-Olsen, There is NOTHING Else for You to Do If You Have Any Questions or Have Not Yet Received a BLUE Proxy Card, Please Contact Sarissa’s Proxy Solici...
Summary Despite recent data hiccups for Guardant Health, Inc., you can expect much more upsides to this stock. The flagship Guardant360 recently gained FDA approval as a companion diagnostic for the breast-cancer drug, Orsedu. Meanwhile, Guardant also formed a strategic partnership ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...